The effect of the levels of serum、EBC ET-1 and serum T lymphocyte subtypes in lung cancer treatment with thymo-penti n and chemotherapy

Gaowa JIN,Yingchun QIN,Yongli GE,Wei LUAN,Gaowa WUYUN

DOI: https://doi.org/10.3969/j.issn.1671-6450.2016.09.005

2016-01-01

Abstract:Objective To observe the clinical effect of thymic peptide combined with chemotherapy in the treatment of lung cancer and its effect on the levels of ET-1 and T lymphocyte subtypes .Methods One 116 cases of patients with lung cancer were selected , which were treated in hospital from October 2012 to October 2015 , and they were divided into the obser-vation group (58 cases) and control group (58 cases).The patients of two groups were treated with Antiemetic , diuretic hy-dration and prevention of phlebitis before chemotherapy .The patients of control group with small cell lung cancer were treated with EP chemotherapy .The patients of control group with non-small cell lung cancer were treated with TP chemotherapy .On the basis of control group, the patients of observation group were treated with thymopentin ( 10 mg, intramuscular injection , 1 times /d, continuous application for 15d).A course of treatment were 15d, and with a total of four courses.Observe the clinic results, occurrence of adverse reactions , EORTC QLQ-C30 quality of life questionnaire score , changes of serum and EBC ET-1,serum ALB, CD4 +, CD8 +, CD4 +/CD8 +, NK of two groups.Results After chemotherapy, the patients of the observation group got a total efficiency of 63.8%, which was significantly better than the 56.9%of the control group (χ2 =4.772, P =0.029); In the terms of ET-1, the patients of two groups were all significantly decreased than before ( P <0.05), and the patients of the observation group got more significant decline ( t =18.193, t=15.405, P =0.000, P =0.000);In the terms of ALB, CD4 +, CD8 +, CD4 +/CD8 +, NK and QOL, the patients of two groups were all significantly improved than before ( P <0.05), and the patients of the observation group got more significant improvement ( t =5.031, t =5.676, t =2.532, t =4.901, t =7.577;P =0.000, P =0.000, P =0.006, P =0.000, P =0.000);the patients of the observation group got a incidence of gastrointestinal reactions of 15.5%, which was significantly less than the 39.6%of&nbsp;the control group (χ2 =8 6.458, P =0.004 ).Conclusion With treating patients with lung cancer , thymopentin combined with chemotherapy is effective to reduce the level of ET-1, inhibit tumor metastasis, and improve the immune function and the quality of life of patients .